Table 4.

Comparison of our study with available literature

Study	DiNardo CD et al. (2019) [14]	Wei et al. (2018) [20]	Aldoss et al. (2018) [21]	DiNardo et al. (2018) [22]	Winters AC et al. (2019) [23]	DiNardo et al. (2020) [27]	Wei et al. [28]	Our study
Patient population	ND% (n=145)	ND% (n=82)	R/R^ (n=33)	R/R^ (n=39)	ND% (n=33)/(n=36)	ND% (n=433)	ND% (n=211)	ND%+R/R^ (n=24)
Venetoclax (Ven) along with -	HMAs¶ (Aza@/Dac#), LDAC*	LDAC*	HMAs¶ (Aza@/Dac#)	HMAs¶ (Aza@/Dac#), LDAC*	HMAs¶	HMA¶+Ven (n=286) vs HMA¶+placebo (n=145)	LDAC*+Ven (n=143) vs LDAC*+placebo (n=68)	HMAs¶ (Aza)@
Venetoclax dose (mg)/duration (days)	400 OD (28)	600 OD (28)	400 OD (28)	400/600 OD (14-28)	400 OD (28)	400 OD (28)	600 OD (28)	400 OD (14-28)
CR/CRi¥ (%)	67	54	51.5	12	63/84	66.4 vs 28.3	48 vs 13	58.3
Median Time to CR (months)	2.1	2.5	2	1	1	1.3	n/a(	2
CR duration (months)	11.3	8.1	8.9	n/a	11/not reached	17.5 vs 13.3	n/a(	8.1
Grade 3-4 leukopenia (%)	31	34	n/a	100	40 (n=28)	21 vs 12	46 vs 16 (neutropenia)	70
% mortality	8 (60-day)	6 (30-day)	n/a(	12 (30-day)	13 (30-day)	7 vs 6 (30-day)	13 vs 16 (30-day)	8 (60-day)
FN$	43%	42%	42%	72%	n=14	42 vs 19	32 vs 29	36 (33%) [All cycles]
								32 (64%) [First 2 cycles]
TLS&	n=0	n=2	n/a(	n=0	n/a(	n/a(	6 vs 0	n=2 (1.8%)
OS£	17.5 months	10 months	53% (1 year)	3 months	12 months/29 months	14.6 months vs 9.1 months	7.2 months vs 4.1 months	8 months (55.8%, 1 year)
								(whole cohort),
								15 months (responders)

^$FN: Febrile neutropenia;

^¥CR/CRi: Complete Remission/Complete Remission with Incomplete Hematologic Recovery;

^*LDAC: Low dose Cytarabine;

^&TLS: Tumor Lysis syndrome;

^£OS: Overall survival;

^¶HMA: Hypomethylating agents;

^@Aza: azacytidine;

^#- Dac: Decitabine;

^%- ND: newly diagnosed;

^{^}- R/R: Relapsed/refractory;

⁽- n/a: not available.